TetrAnflu (Sinovac Biotech Ltd.)

TetrAnflu is a quadrivalent inactivated split-virion influenza vaccine developed by Sinovac Biotech for seasonal prophylaxis. Approved in China in June 2020 for individuals aged three years and older, and later expanded to include infants as young as six months, the vaccine contains hemagglutinin (HA) antigens from four WHO-recommended influenza strains: two A subtypes (H1N1 and H3N2) and two B lineages (Victoria and Yamagata). The manufacturing process involves cultivating the virus in embryonated chicken eggs, followed by purification, chemical inactivation, and disruption into split virions. TetrAnflu works by stimulating the immune system to produce neutralizing antibodies that target the viral HA proteins, thereby preventing viral attachment to host cells and providing protection against seasonal influenza infection. It has demonstrated non-inferior immunogenicity and a favorable safety profile compared to trivalent vaccines in various clinical settings.

Brand names

TetrAnflu

Other names

Sinovac quadrivalent influenza vaccineQuadrivalent influenza vaccine (Sinovac Biotech)QIIVInfluenza Vaccine (Split Virion), Inactivated, QuadrivalentAnflu Quadrivalent